Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study

Yamauchi, Ichiro, Sakane, Yoriko, Fukuda, Yorihide, Fujii, Toshihito, Taura, Daisuke, Hirata, Masakazu, Hirota, Keisho, Ueda, Yohei +6 more·2017·Thyroid
DOI 10.1089/thy.2016.0562

Cited by (168)

Items 101–168 of 168

  1. Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes: a multicenter retrospective study
    Haoting Zhang, Jing Zheng, Chenyi Ren, Chenlin Ye, Xiaoyu O. Wu, Xiaodong Lv, Yuping Li, Jianya Zhou, Jianying Zhou · 2025 · BMC Pulmonary Medicine
  2. Environmental factors and anatomic pathology of the thyroid gland: review of literature
    Manuel Lora Gonzalez, Rebecca D. Chernock, Mena Mansour · 2020 · Diagnostic histopathology
  3. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
    Ichiro Yamauchi, Takuro Hakata, Taku Sugawa, Daisuke Kosugi, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Norio Harada et al. · 2023 · Endocrine Journal
  4. Morphological changes of the thyroid gland as a new radiographic marker for lung cancer treatment efficacy of immune checkpoint inhibitors
    Tomohiro Itonaga, Kazuhiro Saito, Norihiko Ikeda, Ryuji Mikami · 2020 · Acta Radiologica
  5. Thyroid Dysfunction from Treatments for Solid Organ Cancers
    Anupam Kotwal, Donald S.A. McLeod · 2022 · Endocrinology and Metabolism Clinics of North America
  6. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors
    Hidefumi Inaba, Hiroyuki Ariyasu, Hisako Okuhira, Yuki Yamamoto, Hiroaki Akamatsu, Masahiro Katsuda, Masatoshi Jinnin, Isao Hara, Takashi Akamizu · 2020 · Trends in Immunotherapy
  7. Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
    Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai · 2025 · BMC Cancer
  8. Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
    Sara Salehi Hammerstad, Hanna J. Lee, Yaron Tomer, Mihaela Stefan–Lifshitz · 2025 · Journal of Endocrinological Investigation
  9. Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review
    Ying Zan, Yedong Wei, Wenxue Zhang, Xiaolu Gao, Jigang Si · 2025 · Medicine
  10. Lesions in endocrine glands as a complication of immunotherapy in the practice of oncologist
    Nurana F. Nuralieva, Ekaterina Anatol'evna Troshina, Galina Afanas'evna Mel'nichenko · 2019 · Clinical and experimental thyroidology
  11. T3 and T4 autoantibodies: emerging biomarkers for evaluating thyroid disorders
    Jiameng Liu, Chaoming Mao, Xueqian Mao, Xi Wang, Tingting Zheng, Liyang Dong, Yufei Mao · 2025 · Frontiers in Endocrinology
  12. Autoimmunity in the era of immune checkpoint inhibitors: the evolving epidemiology of autoimmune diseases and the possible impact of COVID-19
    Naim Mahroum, Abdulrahman Elsalti, Mohamed Alsharif, Abdullah Jabri, Abderrahman Ouban · 2026 · Autoimmunity Reviews
  13. Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibition for Malignancies
    Shlomit Shalitin · 2024 · Hormone Research in Paediatrics
  14. Signal mining and analysis of influencing factors for adverse events of Nivolumab and Cetuximab in the treatment of head and neck cancer based on the US FAERS database
    Yi Tang, Yongchuan She, Danping Chen, Yibo Zhou, Zhai Liu, Zhihang Chen, Jun Wan, Ren Yu · 2025 · Frontiers in Immunology
  15. Painful acute thyroiditis following a first cure of Ipilimumab plus Nivolumab for metastatic melanoma
    Henri Montaudié, Alexandra Picard, Patricia Panaïa‐Ferrari, Fériel Boukari, Thierry Passeron, Jean‐Louis Sadoul, Françoise Brücker-Davis · 2018 · Melanoma Research
  16. Criteria of metabolic response to immunotherapy
    Jorge Mucientes Rasilla, Lourdes Gutiérrez Sanz · 2019 · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
  17. Allopurinol-induced hypersensitivity syndrome followed by painless thyroiditis in a patient with asymptomatic hyperuricemia
    Xiaolin Chen, Yili Cai, Xin Ge · 2020 · Archives of Medical Science
  18. An Unusual Etiology of Hypothyroidism and New-Onset Insulin-Dependent Diabetes: A Rare Side Effect of Nivolumab
    Halah Alchalabi, Safa Albustani, Nusha Fareen, Ndausung Udongwo, Saira Chaughtai, Soemiwati Weidris Holland · 2022 · Cureus
  19. Nivolumab-induced thyroid dysfunction in patients with lung cancer
    Ana Maria Ramos-Levi, Jacobo Rogado, J.M. Sánchez-Torres, Rámón Colomer, Mónica Marazuela · 2019 · Endocrinología Diabetes y Nutrición (English ed )
  20. Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients
    Jee Hee Yoon, Min‐Ho Shin, Hee Nam Kim, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho‐Cheol Kang · 2021 · Endocrinology and Metabolism
  21. Painless thyroiditis mimicking relapse of hyperthyroidism during or after potassium iodide or thionamide therapy for Graves’ disease resulting in remission
    Ken Okamura, Kaori Sato, Megumi Fujikawa, Sachiko Bandai, Hiroshi Ikenoue, Takanari Kitazono · 2022 · Endocrine Journal
  22. Clinical Significance of Thyroid Autoantibodies in Differential Diagnosis and Predicting the Course of Programmed Cell Death Protein-1 Inhibitor-Induced Thyroid Dysfunction
    Li Li, Xiaoxia Ding, Xihui Zhang, Shuangming Kong, Ming Chen · 2024 · Endocrine Practice
  23. Changes in thyroid hormone levels indicate immunotherapy efficacy in gastric cancer
    Min Xiao, Lan Qian, Qiu Zhao, Jian Ma, Qianxiao Li, Qian Liu, Zhiyan Bi · 2025 · Oncology Letters
  24. Sex differences in thyroid dysfunction onset timing induced by immune checkpoint inhibitors: JADER disproportionality analysis
    Naohito Ide, Yuki Tsuruta, Ken-ichi Sako, Tomoji Maeda · 2026 · Expert Opinion on Drug Safety
  25. Endocrine adverse events in patients with malignant neoplasms receiving treatment with immune checkpoint inhibitors
    Kristina Zherebchikova, Yulia P. Sych, M. Amosova, Marina I Sekacheva, Valentin V. Fadeev, A. A. Vilenskiy · 2022 · Russian Medical Inquiry
  26. Transient Thyroiditis Followed by Exacerbation of Hypothyroidism After Immune Checkpoint Inhibitor Therapy (Nivolumab and Ipilimumab) in a Patient With Pre-existing Autoimmune Hypothyroidism: A Case Report
    Guy Hayakawa, Maya M. Leibowitz, Sudipta Datta, Samson Oghenetsovwe Oyibo · 2023 · Cureus
  27. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
    Luigi Liguori, Angelo Luciano, Giovanna Polcaro, Alessandro Ottaiano, Marco Cascella, Francesco Perri, Stefano Pepe, Francesco Sabbatino · 2023 · Biomedicines
  28. Immunotherapy and Thyroid Dysfunction
    Maria Laura Gregorio, Juan Gómez, Surender Arora, Anil Ramachandran, Amol Madan Takalkar · 2020 · Clinical Nuclear Medicine
  29. Novel thyroid-specific autoantibodies in patients with immune-related adverse events involving the thyroid gland
    Ichiro Yamauchi, Akihiro Yasoda, Takuro Hakata, Takafumi Yamashita, Keisho Hirota, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Masakatsu Sone, Nobuya Inagaki · 2024 · Thyroid Science
  30. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
    Han-Sang Baek, Chaiho Jeong, Kabsoo Shin, Jaejun Lee, Dong‐Jun Lim, Moo Il Kang, Jeonghoon Ha · 2021 · Research Square
  31. The efficacy and safety of atezolizumab, nivolumab, and pembrolizumab as second-line therapy for non-small-cell lung cancer: preliminary data
    Н. К. Мазина, P. V. Mazin · 2018 · P A Herzen Journal of Oncology
  32. ENDOCRINE TOXICITY OF IMMUNE CHECKPOINT INHIBITORS IN CLINICAL PRACTICE
    Sufia Safina, G. Mukhamed’yarova, V. Dimitrieva · 2023 · Oncologia i radiologia Kazakhstana
  33. Surgical Management of Destructive Thyroiditis Triggered by Neoadjuvant Immune Checkpoint Inhibitor Therapy in Locally Advanced Non-Small Cell Lung Cancer: A Case Report
    Sachi Kawagishi, Tōru Kimura, Kenji Kimura, Eriko Fukui, Takashi Kanou, Naoko Ose, Yasushi Shintani · 2025 · Surgical Case Reports
  34. Combined immune checkpoint inhibitor–induced type 1 diabetes: a rare but serious endocrinopathy
    Kasra Emami, Sonia Goyal, VISHAL AKULA, Peggy Nana Ama Amoakohene · 2026 · JCEM Case Reports
  35. Endocrine Toxicities of Immunotherapy
    Manu Raj Pandey, Itivrita Goyal, Marc S. Ernstoff · 2020 · Elsevier eBooks
  36. Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy
    Рашида Вахидовна Орлова, Natalia V. Zhukova, Anna M. Malkova, Yehuda Shoenfeld · 2022 · Cancer Treatment and Research Communications
  37. Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies
    Annu Susan George, Cornelius James Fernandez, Dilip Eapen, Joseph M Pappachan · 2021 · touchREVIEWS in Endocrinology
  38. Painless Thyroiditis Induced by Immune Checkpoint Inhibitors in a Patient with Small Cell Lung Cancer
    Feliciano Maria Jose Burchés, Lazaro Antonia Perez, Torres Juan Francisco Merino · 2018 · Clinical Medical Reviews and Case Reports
  39. Criterios de respuesta metabólica a la inmunoterapia
    Jorge Mucientes Rasilla, Lourdes Gutiérrez Sanz · 2019 · Revista Española de Medicina Nuclear e Imagen Molecular
  40. Schilddrüsenfunktionsstörungen unter Immuncheckpoint-Inhibitor-Therapie
    Verena Theiler‐Schwetz, Christian Trummer, Erika Richtig, Georg Richtig, Stefan Pilz · 2020 · Journal für Klinische Endokrinologie und Stoffwechsel
  41. Graves’ Disease
    Sanjay Saran · 2021 · IntechOpen eBooks
  42. Nivolumab
    2017 · Reactions Weekly
  43. Key differences between anti-PD-1/PD-L1 inhibitors
    Natalia V. Zhukova, Рашида Вахидовна Орлова, Екатерина Александровна Каледина, Полина Андреевна Наймушина, Anna M. Malkova, Natalia P. Beliak · 2022 · Meditsinskiy sovet = Medical Council
  44. Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database
    Nobuaki Matsui, Kyoji Kouda, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano, Kohji Naora, Takashi Kitahara · 2021 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
  45. Correlation between immune-related adverse events and long-terms outcome in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: a retrospective study
    Jiangmin Zhou, Zhiwei Zhang, Biao Wu · 2022 · Research Square
  46. Case 5: A 41-Year-Old Woman With Palpitation
    Ji Won Yang, Kabsoo Shin, Jeongmin Lee, Jeonghoon Ha, Dong‐Jun Lim, Han-Sang Baek · 2022 · Journal of Korean Medical Science
  47. Immunotherapy and Endocrine Oncology
    Macarena Contreras, Juan Cristóbal Sánchez, Pedro Iglesias · 2022 · Springer eBooks
  48. Endocrine Toxicities Related to Immunotherapy
    Mark A Quinn, Paul Carroll, Mamta Joshi · 2022 · Springer eBooks
  49. Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
    Aikaterini Lavrentaki, Georgia Ntali · 2023 · Springer eBooks
  50. Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity
    C. Mehmet Hendekli · 2023 · Journal of Cancer Research and Clinical Oncology
  51. [Correlation Analysis between Thyroid Function Abnormality and Efficacy in Patients with Advanced Non-small Cell Lung Cancer after Immunotherapy].
    Yibo Wang, Xinjuan Wang, Lin Cheng, Guojun Zhang · 2023 · PubMed Central
  52. Thyroid disease-related sleep disorders and its diagnostic and therapeutic recommendations: A literature review
    Qin Yin, Jinfeng Wang, Shu Wang, Yue Sun, Wei Cheng, Yinming Zeng · 2023 · Perioperative Precision Medicine
  53. Immuntherapie mit Checkpointinhibitoren und schilddrüsentypische Komplikationen
    Barbara Kreppel · 2024 · Angewandte Nuklearmedizin
  54. A Case Report and Literature Review of Hypothyroidism Caused by Pembrolizumab
    慧萍 贾 · 2024 · Advances in Clinical Medicine
  55. Immunotherapy-Related Hypothyroidism: Mechanisms and Management
    Selin Çakmak Demir, Dilek Yazıcı · 2024 · IntechOpen eBooks
  56. Immunotherapy for Endocrine Oncology
    Macarena Contreras, Juan Cristóbal Sánchez, Pedro Iglesias · 2024 · Springer eBooks
  57. Are patients with chronic obstructive pulmonary disease at a greater risk for the development of autoimmune thyroiditis as an adverse event of immunotherapy in non-small cell lung cancer treatment?
    Andrej Zečević, Ana Blanka-Protić, Aleksandar Jandrić, Tatjana Adžić‐Vukičević · 2025 · Pathology & Oncology Research
  58. IMUNOTERAPIJOS SUKELTAS SKYDLIAUKĖS FUNKCIJOS SUTRIKIMAS, GYDANT AKIŲ MELANOMĄ: KLINIKINIS ATVEJIS
    Michail Taradaj, Vincas Urbonas, Lina Zabulienė · 2025 · Health Sciences
  59. Immunotherapy for Endocrine Oncology
    Macarena Contreras, Juan Cristóbal Sánchez, Pedro Iglesias · 2025 · Springer eBooks
  60. Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
    Aikaterini Lavrentaki, Georgia Ntali · 2025 · Springer eBooks
  61. Additional file 1 of Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response
    Chen, Zi-Hang, Weihong Zheng, Wu, Chen-Fei, Jia Kou, Yang, Xing-Li, Lin, Li, Jiawei Lv, Sun, Ying, Zhou, Guan-Qun · 2023 · Figshare
  62. Additional file 1 of Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
    Hansang Baek, Jeong, Chaiho, Kabsoo Shin, Lee, Jaejun, Heysun Suh, Lim, Dong-Jun, Kang, Moo Il, Jeonghoon Ha · 2022 · Figshare
  63. Endocrine Toxicities Related to Immunotherapy
    Mark A Quinn, Paul Carroll, M. N. Joshi · 2025 · Springer eBooks
  64. Thyroid Dysfunction Induced by Pembrolizumab: Five Case Reports
    Tingting Zhang, Jing Li, Junru Cai, Xiang Li, Lu Lin · 2026 · Case Reports in Oncology
  65. Clinical outcomes of cancer patients with pre-existing autoimmune thyroid disease treated with PD-(L)-1 inhibitors: a propensity score methodology with inverse probability of treatment weighting retrospective study
    Yun Shi, Qiuyi Wang, Ziqing Ye, Doudou Chen, Taoyue Yang, Yongyue Wei, Xuqin Zheng · 2026 · Frontiers in Endocrinology
  66. Clinical Significance and Research Progress of Thyroid Immune-Related Adverse Events in Immunotherapy for Advanced Non-Small Cell Lung Cancer
    家玮 龚 · 2026 · Advances in Clinical Medicine
  67. Hypothyroidism in patients treated with immune checkpoint inhibitors
    N. Laghmouch, I. Meeusen, Th.B. Twickler · 2026 · Elsevier eBooks
  68. Cell-intrinsic functions of PD-L1 activate autophagy and prevent cytokine-induced apoptosis
    Mihaela Stefan–Lifshitz, Nicola Viola, Olga Meshcheryakova, Crystal Nieves Garcia, Pamela Mattar, Zhengzi Yi, Marie Louise Aoun, John Christopher McAuliffe, Jonathan Smith, Vikas Mehta et al. · 2026 · Science Advances